RU2012121633A - АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ - Google Patents
АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ Download PDFInfo
- Publication number
- RU2012121633A RU2012121633A RU2012121633/04A RU2012121633A RU2012121633A RU 2012121633 A RU2012121633 A RU 2012121633A RU 2012121633/04 A RU2012121633/04 A RU 2012121633/04A RU 2012121633 A RU2012121633 A RU 2012121633A RU 2012121633 A RU2012121633 A RU 2012121633A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- group
- cycloalkyl
- compound
- atoms
- Prior art date
Links
- 0 *c1cc(CS([n](cc2)cc2NC(c2ncccc2)=O)(=O)=O)ccc1 Chemical compound *c1cc(CS([n](cc2)cc2NC(c2ncccc2)=O)(=O)=O)ccc1 0.000 description 6
- FXFUHZZXWDTTLB-UHFFFAOYSA-N Cc([o]1)ccc1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O Chemical compound Cc([o]1)ccc1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O FXFUHZZXWDTTLB-UHFFFAOYSA-N 0.000 description 1
- LIVAPIWBIQYQLE-UHFFFAOYSA-N Cc(cc1)c(C)cc1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O Chemical compound Cc(cc1)c(C)cc1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O LIVAPIWBIQYQLE-UHFFFAOYSA-N 0.000 description 1
- QZYISZRZKOLAEI-UHFFFAOYSA-N Cc(cc1)cc(C)c1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O Chemical compound Cc(cc1)cc(C)c1S([n](cc1)cc1NC(c1ncccc1)=O)(=O)=O QZYISZRZKOLAEI-UHFFFAOYSA-N 0.000 description 1
- NAXOYVFPVPGDLQ-UHFFFAOYSA-N Cc(cc1)cnc1C(CNc(cc1)c[n]1S(Cc(cc1)ccc1Cl)(=O)=O)=O Chemical compound Cc(cc1)cnc1C(CNc(cc1)c[n]1S(Cc(cc1)ccc1Cl)(=O)=O)=O NAXOYVFPVPGDLQ-UHFFFAOYSA-N 0.000 description 1
- ZFIVHSMAJJJNRR-UHFFFAOYSA-N Cc1cccc(S([n](cc2)cc2NC(C2=NCCS2)=O)(=O)=O)c1 Chemical compound Cc1cccc(S([n](cc2)cc2NC(C2=NCCS2)=O)(=O)=O)c1 ZFIVHSMAJJJNRR-UHFFFAOYSA-N 0.000 description 1
- MUKDHQLJSDZPCV-UHFFFAOYSA-N Cc1cccc(S([n](cc2)cc2NC(c2ccccn2)=O)(=O)=O)c1 Chemical compound Cc1cccc(S([n](cc2)cc2NC(c2ccccn2)=O)(=O)=O)c1 MUKDHQLJSDZPCV-UHFFFAOYSA-N 0.000 description 1
- PEAMTLSADCDOAT-UHFFFAOYSA-N O=C(c1c[s]cn1)Nc(cc1)c[n]1S(Cc1ccccc1)(=O)=O Chemical compound O=C(c1c[s]cn1)Nc(cc1)c[n]1S(Cc1ccccc1)(=O)=O PEAMTLSADCDOAT-UHFFFAOYSA-N 0.000 description 1
- WLMJORLOXICLJA-UHFFFAOYSA-N O=C(c1c[s]nn1)Nc(cc1)c[n]1S(Cc1ccccc1Cl)(=O)=O Chemical compound O=C(c1c[s]nn1)Nc(cc1)c[n]1S(Cc1ccccc1Cl)(=O)=O WLMJORLOXICLJA-UHFFFAOYSA-N 0.000 description 1
- MEGDFHWVDNNSJG-UHFFFAOYSA-N O=C(c1ccccn1)Nc(cc1)c[n]1S(Cc(cccc1)c1Cl)(=O)=O Chemical compound O=C(c1ccccn1)Nc(cc1)c[n]1S(Cc(cccc1)c1Cl)(=O)=O MEGDFHWVDNNSJG-UHFFFAOYSA-N 0.000 description 1
- XFVHUBLLXVYMHA-UHFFFAOYSA-N O=C(c1ccccn1)Nc(cc1)c[n]1S(c1ccccc1)(=O)=O Chemical compound O=C(c1ccccn1)Nc(cc1)c[n]1S(c1ccccc1)(=O)=O XFVHUBLLXVYMHA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25406209P | 2009-10-22 | 2009-10-22 | |
| US61/254,062 | 2009-10-22 | ||
| US29272510P | 2010-01-06 | 2010-01-06 | |
| US61/292,725 | 2010-01-06 | ||
| PCT/US2010/053837 WO2011050316A1 (en) | 2009-10-22 | 2010-10-22 | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012121633A true RU2012121633A (ru) | 2013-11-27 |
Family
ID=43900711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012121633/04A RU2012121633A (ru) | 2009-10-22 | 2010-10-22 | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| RU2012121630/04A RU2012121630A (ru) | 2009-10-22 | 2010-10-22 | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012121630/04A RU2012121630A (ru) | 2009-10-22 | 2010-10-22 | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9180192B2 (enExample) |
| EP (2) | EP2490537A4 (enExample) |
| JP (2) | JP2013508413A (enExample) |
| KR (2) | KR20120129869A (enExample) |
| CN (2) | CN102665417A (enExample) |
| AU (2) | AU2010310440A1 (enExample) |
| BR (2) | BR112012009576A2 (enExample) |
| CA (2) | CA2779298A1 (enExample) |
| IL (2) | IL219297A0 (enExample) |
| MX (2) | MX2012004771A (enExample) |
| RU (2) | RU2012121633A (enExample) |
| WO (2) | WO2011050316A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN102933572B (zh) | 2010-04-07 | 2015-01-07 | 霍夫曼-拉罗奇有限公司 | 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法 |
| JP6120861B2 (ja) | 2011-09-27 | 2017-04-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 |
| EP2853532B1 (en) | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) * | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EA202090467A1 (ru) | 2017-08-16 | 2020-06-18 | Вандербилт Юниверсити | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| US20220089609A1 (en) | 2018-07-26 | 2022-03-24 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CA3134635A1 (en) | 2019-04-03 | 2020-10-08 | Aligos Therapeutics, Inc. | Pyrrole compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2005007096A2 (en) * | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| KR100929942B1 (ko) | 2005-03-04 | 2009-12-04 | 에프. 호프만-라 로슈 아게 | Ｍｇｌｕｒ５ 길항제로서 피리딘-2-카복사미드 유도체 |
| KR101024227B1 (ko) * | 2005-11-21 | 2011-03-29 | 시오노기세이야쿠가부시키가이샤 | 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물 |
| US8110530B2 (en) * | 2006-12-21 | 2012-02-07 | Kumiai Chemical Industry Co., Ltd. | Herbicidal composition |
| CL2008000835A1 (es) * | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| TWI443090B (zh) * | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
-
2010
- 2010-10-22 RU RU2012121633/04A patent/RU2012121633A/ru not_active Application Discontinuation
- 2010-10-22 BR BR112012009576A patent/BR112012009576A2/pt not_active IP Right Cessation
- 2010-10-22 EP EP10825772.6A patent/EP2490537A4/en not_active Withdrawn
- 2010-10-22 BR BR112012009574A patent/BR112012009574A2/pt not_active IP Right Cessation
- 2010-10-22 RU RU2012121630/04A patent/RU2012121630A/ru not_active Application Discontinuation
- 2010-10-22 CN CN2010800589745A patent/CN102665417A/zh active Pending
- 2010-10-22 CA CA2779298A patent/CA2779298A1/en not_active Abandoned
- 2010-10-22 MX MX2012004771A patent/MX2012004771A/es not_active Application Discontinuation
- 2010-10-22 WO PCT/US2010/053837 patent/WO2011050316A1/en not_active Ceased
- 2010-10-22 KR KR1020127013201A patent/KR20120129869A/ko not_active Withdrawn
- 2010-10-22 US US13/503,644 patent/US9180192B2/en active Active
- 2010-10-22 CN CN2010800589726A patent/CN102665411A/zh active Pending
- 2010-10-22 US US13/503,645 patent/US20130338154A1/en not_active Abandoned
- 2010-10-22 WO PCT/US2010/053825 patent/WO2011050305A1/en not_active Ceased
- 2010-10-22 AU AU2010310440A patent/AU2010310440A1/en not_active Abandoned
- 2010-10-22 JP JP2012535430A patent/JP2013508413A/ja not_active Withdrawn
- 2010-10-22 JP JP2012535428A patent/JP2013508412A/ja active Pending
- 2010-10-22 AU AU2010310518A patent/AU2010310518A1/en not_active Abandoned
- 2010-10-22 CA CA2779292A patent/CA2779292A1/en not_active Abandoned
- 2010-10-22 KR KR1020127013191A patent/KR20120088755A/ko not_active Withdrawn
- 2010-10-22 MX MX2012004774A patent/MX2012004774A/es unknown
- 2010-10-22 EP EP10825779.1A patent/EP2490529A4/en not_active Withdrawn
-
2012
- 2012-04-19 IL IL219297A patent/IL219297A0/en unknown
- 2012-04-19 IL IL219296A patent/IL219296A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013508413A (ja) | 2013-03-07 |
| AU2010310518A1 (en) | 2012-06-07 |
| IL219297A0 (en) | 2012-06-28 |
| WO2011050316A1 (en) | 2011-04-28 |
| US9180192B2 (en) | 2015-11-10 |
| JP2013508412A (ja) | 2013-03-07 |
| WO2011050305A1 (en) | 2011-04-28 |
| EP2490529A4 (en) | 2013-08-28 |
| EP2490537A1 (en) | 2012-08-29 |
| EP2490529A1 (en) | 2012-08-29 |
| BR112012009576A2 (pt) | 2019-09-24 |
| KR20120088755A (ko) | 2012-08-08 |
| US20130338154A1 (en) | 2013-12-19 |
| CN102665417A (zh) | 2012-09-12 |
| US20130040944A1 (en) | 2013-02-14 |
| CA2779298A1 (en) | 2011-04-28 |
| MX2012004774A (es) | 2012-06-01 |
| CA2779292A1 (en) | 2011-04-28 |
| EP2490537A4 (en) | 2013-08-28 |
| CN102665411A (zh) | 2012-09-12 |
| BR112012009574A2 (pt) | 2019-09-24 |
| IL219296A0 (en) | 2012-06-28 |
| RU2012121630A (ru) | 2013-11-27 |
| KR20120129869A (ko) | 2012-11-28 |
| MX2012004771A (es) | 2012-05-23 |
| AU2010310440A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012121633A (ru) | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| AU2021290277B2 (en) | Novel methods | |
| RU2012121631A (ru) | АРИЛ- И ГЕТЕРОАРИЛСУЛЬФОНЫ КАК АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| RU2012114770A (ru) | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| JP2013526544A5 (enExample) | ||
| SI3002283T1 (en) | Thiazole derivatives | |
| JP5926272B2 (ja) | Ｗｎｔ経路のアンタゴニストとしてのクロメン誘導体及びそれらの類似体 | |
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| JOP20190058B1 (ar) | مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها | |
| CA3198575A1 (en) | Formulations and methods for treating acute cannabinoid overdose | |
| EA200870224A1 (ru) | Бензо[f]изоиндол-2-илфенильные производные уксусной кислоты в качестве агонистов рецепторов ep | |
| CN101415707A (zh) | 杂双环酰胺衍生物 | |
| CA2663965A1 (en) | Pyrazolopyrimidine derivative and use thereof as an anticancer agent | |
| JP2016536350A (ja) | キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法 | |
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина | |
| Kwon et al. | Design, synthesis, and evaluation of a water-soluble antofine analogue with high antiproliferative and antitumor activity | |
| CA2983313A1 (en) | Mixed disulfide conjugates of thienopyridine compounds and uses thereof | |
| EP3307724B1 (en) | (z)-2-(1h-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile derivatives and related compounds with lysosome inhibitory and anti-mitotic activity for treating hyperproliferative diseases | |
| CA2797762A1 (en) | Imidazo[1,2-a]pyridine derivative | |
| CN112521358A (zh) | 一种长效低成瘾性hnk衍生物在制备药物中的应用 | |
| CN1498109A (zh) | 膀胱感觉过敏治疗剂 | |
| JP2009515862A (ja) | 増殖症の治療のためのロスコビチンとｈｄａｃ阻害剤との組合せ | |
| ITMI20110208A1 (it) | Eterocicli ad attivita' antiipertensiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150119 |